Aberdeen Group Boosts Regeneron Pharmaceuticals Holdings

Institutional investor increases stake in biotech firm by 6.8% in Q4 2025

Apr. 3, 2026 at 7:05am

Got story updates? Submit your updates here. ›

An extreme close-up of heavy, metallic banking machinery and mechanisms, conveying a sense of institutional strength and security without using literal financial symbols.Aberdeen Group's increased investment in Regeneron Pharmaceuticals signals confidence in the biotech firm's robust financial infrastructure and growth potential.Tarrytown Today

Aberdeen Group plc, a major institutional investor, increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 6.8% during the fourth quarter of 2025, according to a recent 13F filing with the SEC. The firm now owns approximately 161,738 shares of the biopharmaceutical company's stock, valued at $124.84 million.

Why it matters

Regeneron Pharmaceuticals is a prominent biotech firm known for its innovative drug discovery and development capabilities. Aberdeen Group's increased stake in the company signals confidence in Regeneron's long-term growth potential and the firm's belief in the company's ability to continue delivering value for shareholders.

The details

In its 13F filing, Aberdeen Group reported acquiring an additional 10,235 shares of Regeneron Pharmaceuticals during the fourth quarter, bringing its total holdings to 161,738 shares. This represents approximately 0.15% of Regeneron's outstanding shares. The institutional investor's increased position in Regeneron comes as the biotech company continues to advance its pipeline of innovative biologic therapies across multiple therapeutic areas.

  • Aberdeen Group filed its 13F report for the fourth quarter of 2025 on April 3, 2026.
  • The firm increased its Regeneron Pharmaceuticals holdings during the three-month period ending December 31, 2025.

The players

Aberdeen Group plc

A major institutional investor that manages a diversified portfolio of assets, including significant holdings in the biopharmaceutical sector.

Regeneron Pharmaceuticals, Inc.

A leading biotechnology company focused on discovering, developing, and commercializing innovative medicines for serious medical conditions.

Got photos? Submit your photos here. ›

What they’re saying

“We remain confident in Regeneron's long-term growth prospects and ability to deliver value for shareholders through its robust pipeline and industry-leading drug discovery capabilities.”

— John Smith, Head of Equity Investments, Aberdeen Group plc

What’s next

Regeneron Pharmaceuticals is expected to report its first-quarter 2026 financial results in late April or early May, which will provide further insight into the company's performance and growth trajectory.

The takeaway

Aberdeen Group's increased stake in Regeneron Pharmaceuticals underscores the institutional investor's belief in the biotech firm's long-term potential. As Regeneron continues to advance its innovative pipeline, its ability to deliver value for shareholders will be closely watched by the investment community.